NK cell therapy for T-cell lymphoma or leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new treatment using natural killer (NK) cells that are specially created in the lab to find and attack cancer cells that have a protein called CD5 on their surface. The treatment is given along with chemotherapy to help the NK cells work better. It may be an option for people with certain types of T-cell lymphoma or leukemia that have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- Your cancer must show a marker called CD5 on at least 30% of the cancer cells.
- You must have a specific type of T-cell lymphoma or T-cell leukemia, such as T-ALL, T-PLL, peripheral T-cell lymphoma, or similar.
- You should be in reasonably good health, able to take care of yourself, and have adequate kidney, liver, heart, and lung function.
- You must not have had a stem cell transplant in the last 12 weeks.
- You must be willing to sign a consent form and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment using natural killer (NK) cells combined with antibodies to fight a type of blood cancer called acute myeloid leukemia (AML). It is for people whose AML has come back or not improved with standard treatments.
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
This trial tests a new type of cell therapy called CAR NK cells that are designed to find and attack lymphoma cells carrying a marker called CD70. It is for people whose lymphoma either did not go away after the first treatment or came back within a year.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
This trial tests a new therapy using your own immune cells (NK cells) engineered to find and kill cancer cells that carry the CD5 protein. It is for people with T-cell acute lymphoblastic leukemia or certain T-cell lymphomas that have not responded to treatment or have returned.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.